Full Press Release Details
YS Biopharma Announces Board Changes and Strategic
Leadership Appointments in Chinese Subsidiaries
GAITHERSBURG, Md., Mar. 5, 2024 /PRNewswire/ --
YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated
to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases
and cancer, today announced changes to its board of directors (the "Board") and key strategic appointments within its wholly-owned
subsidiaries in China.
Each of Mr. Bo Tan and Mr. Shaojing Tong has resigned
as a director of the Company for personal reasons, effective from February 29, 2024. Their resignation did not result from any disagreement
with the Company on any matter relating to the Company's operations, policies, or practice. Following such resignation, the Board currently
consists of ten directors, including: (1) Dr. Ajit Shetty (Chairperson of the Board and the Nominating and Corporate Governance Committee),
(2) Dr. Hui Shao (David), (3) Ms. Chunyuan Wu (Brenda), (4) Dr. Viren Mehta (Chairperson of Compensation Committee), (5) Ms. Rachel Yu
(Chairperson of Audit Committee), (6) Dr. Jin Wang, (7) Mr. Haitao Zhao, (8) Mr. Henry Chen, (9) Mr. Pierson Yue Pan, and (10) Mr. Yuntao
Furthermore, YishengBio (Hong Kong) Holdings Limited
("YishengBio Hong Kong"), a wholly-owned subsidiary of the Company, has designated Ms. Chunyuan (Brenda) Wu, the Company's
CFO and a Board director, as the new legal representative and executive director of Beijing Yisheng Biotechnology Co., Ltd., one of YishengBio
Hong Kong's wholly-owned subsidiaries in China, for a term of 3 years, effective from March 2, 2024. Additionally, YishengBio Hong Kong
has appointed Mr. Gang Li, the Company's Head of Marketing and Sales, as the new legal representative and chairman of the board of directors
of Liaoning Beijing Yisheng Biopharmaceutical Co., Ltd., another wholly-owned subsidiary in China, for a term of 3 years, effective from
Following such new appointments, the senior officers
of YS Biopharma includes (1) Dr. Hui Shao (David, President & CEO, Director), (2) Ms. Chunyuan Wu (Brenda, CFO), (3) Dr. Zenaida Mojares
(Chief Medical Officer), (4) Mr. Gang Li (Head of Marketing and Sales), and (5) Dr. Yuan Liu (Head of Vaccine Research).
YS Biopharma is a global biopharmaceutical company
dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious
diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a series of preventive and therapeutic
biologics with a potential for improved Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles vaccines. YS Biopharma operates in China,
the United States, Singapore and the Philippines, and is led by a management team that combines rich local expertise and global experience
in the bio-pharmaceutical industry. For more information, please visit investor.ysbiopharm.com.
Investor Relations Contact
Tel: +1 (212) 537-4035
Email: YSBiopharma.IR@icrinc.com